Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04773730
Other study ID # regional block
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 15, 2021
Est. completion date June 3, 2023

Study information

Verified date June 2023
Source Mansoura University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This patient population are at risk of adverse effects secondary to inadequate pain management such as inadequate maternal bonding and late ambulation. Regional analgesia is preferred due to their opioid sparing effects and reduction in related adverse effects but the analgesia from these blocks is not known which one is superior to the other in the context of cesarean section


Description:

The aim of this study is to compare the effect of posterior transversus abdominus plane block and quadratus lumborum type 2 for cesarean delivery. The transversus abdominus plane(TAP) block provides sensory block from T6 to L1 for lower abdominal surgeries. Quadratous lumborum type 2 block, the injection is posterior to the quadratus lumborum muscle. This method has the advantage of a more superficial point of injection with better ultrasonographic resolution. Only one RCT was done in this context by Kalpana Verma and his colleagues comparing quadratus lumborum type 2 and posterior transversus abdominus plane block. That shows marked discrepancy with time to first analgesic request from the quadratus lumborum block in other abdominal surgeries


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date June 3, 2023
Est. primary completion date August 1, 2022
Accepts healthy volunteers No
Gender Female
Age group 20 Years to 40 Years
Eligibility Inclusion Criteria: - American Society of Anesthesiologists physical status II parturient. - Singleton pregnancies with a gestation of at least 37 weeks. - Patients undergoing spinal anesthesia for cesarean deliveryvia a Pfannenstiel incision with exteriorization of the uterus. Exclusion Criteria: - Age < 19 or > 40 years. - Height<150 cm, weight < 60 kg, body mass index (BMI) =35 kg/m2. - Inability to comprehend or participatein pain scoring system. - Contraindications to spinal anesthesia (Coagulopathy, increased intracranial pressure, or local skin infection). - Hypersensitivity to any drugused in the study. - Hypertensive disorders of pregnancy. - Renal impairment or other contraindication to non-steroidal anti-inflammatory drugs. - Significant cardiovascular, renal or hepatic abnormalities. - Patients with history of opoid intake, drug abusers, psychiatric patients.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Posterior transversus abdominus plane block
Twenty mL of bupivacaine 0.25% will be injected in the plane between the transverses abdominus muscle and the fascia deep to the internal oblique muscle on each side
Quadratus lumborum block type 2
Twenty mL of bupivacaine 0.25% will be injected on the posterior surface of quadrates lumborum muscle on each side

Locations

Country Name City State
Egypt El Mansoura El Mansoura

Sponsors (1)

Lead Sponsor Collaborator
Mansoura University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The analgesic duration the time measured from finishing the block till the first request of analgesia by the patient within 24 hours after the surgery
Secondary Postoperative pain at rest 100 centimetres visual analog scale (VAS) for pain, where zero is equal to no pain and hundred indicates the worst possible pain immediately and 1,2,3,4hour at postanesthesia care unit, then in the surgical ward at 6,8,10,12,18 and 24 h
Secondary Postoperative pain on movement (attempted hip flexion) or coughing 100 centimetres visual analog scale (VAS) for pain, where zero is equal to no pain and hundred indicates the worst possible pain immediately and 1,2,3,4hour at postanesthesia care unit, then in the surgical ward at 6,8,10,12,18 and 24 h
Secondary Patient satisfaction poor= 1, fair = 2, good = 3, excellent = 4 24 hours after surgery
Secondary Heart rate beat per minute at 1st, 2nd, 3rd, 4th, 10th, 16th and 22nd hours postoperatively
Secondary Non-invasive blood pressure mmHg at 1st, 2nd, 3rd, 4th, 10th, 16th and 22nd hours postoperatively
Secondary Total postoperative analgesic consumption of of ketolac, paracetamol and fentanyl Patients with visual analog scale more than 30 will receive 30 mg of intravenous ketolac in addition to 1gm paracetamol which will be repeated every 8 hours intravenous infusion of every 8 hours. Intravenous administration of fentanyl bolus doses of 0.5 µg per kg per dose will be given if the visual analog scale remains more than 30 within the first 24 hours after surgery
Secondary Postoperative nausea and vomiting 0= none, 1= mild, 2= moderate and 3= sever within 24 hours after surgery
Secondary Postoperative lower limb weakness reported by the patient during her first walk after surgery within 24 hours after surgery
See also
  Status Clinical Trial Phase
Completed NCT04371705 - Efficacy of Ultrasound Guided Erector Spinae Plane Block N/A
Terminated NCT01473667 - Superficial Cervical Plexus Block for Pacemaker Insertion N/A
Recruiting NCT05652075 - PENG and LFCN Block Versus Lumbar Plexus Block for Postoperative Analgesia After Total Hip Arthroplasty N/A
Recruiting NCT06231355 - Liposomal vs. Conventional Bupivacaine for Pain Control Phase 4
Completed NCT05633329 - Dual Injection ESPB Versus Single Injection ESPB for Laparotomies N/A
Recruiting NCT03777592 - Perioperative Erector Spinae Plane Block in Thoracoscopic Surgery N/A